Report of Foreign Issuer (6-k)
February 05 2018 - 4:47PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February, 2018
Commission File Number: 001-35892
GW PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Other Events
On February 5, 2018, GW Pharmaceuticals
plc (the “Company”) issued a press release announcing its first quarter 2018 financial results and operational progress
and details of a conference call to be held at 4:30 p.m. EST on February 5, 2017 to discuss the results and operational progress.
The press release is attached as Exhibit 99.1 and is incorporated by reference herein. The condensed consolidated income
statement, statement of changes in equity, consolidated balance sheets and consolidated cash flow statements for the three months
ended December 31, 2017 and 2016 and the related notes thereto contained in Exhibit 99.1 to this Form 6-K are incorporated by reference
into the Company’s Form F-3 Registration Statement File No. 333-217329 and Form S-8 Registration Statements File
Nos. 333-204389 and 333-217328, and related Prospectuses, as such Registration Statements and Prospectuses may be
amended from time to time. The other information contained in Exhibit 99.1 shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference
in such a filing.
Exhibits
99.1 Press Release dated February 5, 2018
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Douglas B. Snyder
|
|
Name:
|
Douglas B. Snyder
|
|
Title:
|
Chief Legal Officer
|
|
|
|
Date: February 5, 2018
|
|
|